ARS Pharmaceuticals Shifts Focus to Providers, Cuts Costs Amid Neffy Market Share Growth
Event summary
- $26.2M in Q2 2026 U.S. neffy revenue, up from $12.8M in Q2 2025; total market share hits 5%, doubling year-over-year.
- ARS Pharma appoints Meg Smith as Chief Commercial Officer, effective August 17, 2026, to drive provider-focused commercial strategy.
- Company expects cash flow breakeven by end of 2027 after cutting SG&A expenses by over 40% in 2H 2026.
- Interim Phase 2b trial data for chronic spontaneous urticaria (CSU) expected Q1 2027, targeting unmet need in acute flare management.
The big picture
ARS Pharmaceuticals is pivoting from broad consumer marketing to a provider-centric strategy, aiming to capitalize on neffy’s first-mover advantage as the only needle-free epinephrine option. The move comes amid rising competition in the $3B+ U.S. anaphylaxis market and follows a 100% year-over-year revenue increase for neffy. Success hinges on whether targeted prescriber adoption can offset reduced consumer visibility while supporting ARS Pharma’s path to profitability.
What we're watching
- Provider Adoption
- Whether ARS Pharma’s shift to targeted provider engagement can sustain neffy’s market share growth without consumer marketing.
- Cost Discipline
- The pace at which expense reductions will translate into cash flow breakeven by late 2027 amid ongoing R&D investments.
- CSU Expansion
- How interim Phase 2b trial data in Q1 2027 could position ARS Pharma to capture a high-margin growth opportunity in chronic spontaneous urticaria.